Outcomes of Patients Who Undergo Aggressive Induction Therapy for Secondary Acute Myeloid Leukemia.

The article presents a study that reviews survival of secondary acute myeloid leukemia (SAML) patients receiving aggressive induction chemotherapy. The study shows that the overall survival was 13.6 months and median event-free survival was eight months. It reveals that eight patients passed away shortly after receiving induction therapy due to side effects or the disease. It indicates that the median disease-free survival for patients attaining morphologic complete remission was nine months.